Is This The Turning Point for Inovio?
It seems such a long time ago that Inovio Pharmaceuticals (NASDAQ: INO) was considered one of the leaders in the hunt for a COVID-19 vaccine -- but the biotech was left in the dust by peers and many investors have given up on the stock. In the past 12 months, shares of Inovio are down 45% even as the broader market took off. Let's see whether the company is finally ready to turn things around.